Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biotron Limited ( (AU:BIT) ) has shared an update.
Biotron Limited successfully completed a renounceable rights issue, raising $1,274,589 before costs, and will issue 424,863,077 new fully paid ordinary shares. The funds will support the company’s ongoing commercialisation activities, strategic partnerships for its antiviral programs, and operational costs, demonstrating strong shareholder and management support.
More about Biotron Limited
Biotron Limited operates in the biotechnology industry, focusing on the development and commercialization of antiviral programs. Its primary products include a portfolio of antiviral treatments, with a lead asset known as BIT225, and a promising early-stage Hepatitis B virus program.
YTD Price Performance: 390.0%
Average Trading Volume: 2,000
Technical Sentiment Signal: Sell
Current Market Cap: $3.8M
For detailed information about BIT stock, go to TipRanks’ Stock Analysis page.